Talem Therapeutics, a subsidiary of ImmunoPrecise, and EVQLV announced a new collaboration aimed at accelerating the global effort to develop lead therapeutic and vaccine candidates against the SARS-CoV-2 virus (coronavirus).
EVQLV will perform in silico antibody design and discovery to generate novel, optimized antibody sequences leveraging lead candidate data from IPA’s discovery technologies, as well as previously published sequences. EVQLV plans to utilize its high-speed, evolutionary algorithms with IPA’s expedited B cell Select™ and custom DeepDisplay™ antibody outputs to intelligently discover context-dependent representations that comprise the mutational space of therapeutic candidates for the treatment of SARS-CoV-2 Coronavirus.
“We have been working diligently with EVQLV’s executive team on strategic and operational alignments for the past nine months, an astonishingly fateful advantage under these circumstances, and are able, consequently, to leverage the benefits of this collaboration immediately,” said Dr. Jennifer Bath, President and CEO of IPA. “Our time spent with EVQLV’s management has demonstrated their immense capacity for creativity and thinking outside the box, while absorbing the complexities of IPA’s technologies and outputs. We believe the two teams will create significant therapeutic value together.”
Read the full press release here.